MSANTD3

Across TCGA pan-cancer cohorts, MSANTD3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MSANTD3 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher MSANTD3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MSANTD3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, LUAD, and UCEC are the cancer types where MSANTD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
LUAD	DFS	Median	All	0.252	0.794	<.001	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MSANTD3–DLBC (OS)

Open the DLBC breakdown →